Acolbifene
CAS: 182167-02-8
Ref. 3D-HHA16702
1mg | Ausgelaufen | ||
5mg | Ausgelaufen | ||
10mg | Ausgelaufen | ||
25mg | Ausgelaufen | ||
50mg | Ausgelaufen |
Produktinformation
- 2H-1-Benzopyran-7-ol, 3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, (2S)-
- EM 652
- 2H-1-Benzopyran-7-ol, 3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, (S)-
- Sch 57068
- (2S)-3-(4-Hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-7-ol
Acolbifene is an estrogen receptor antagonist that blocks the effects of estrogen on breast tissue and reduces the risk of developing breast cancer. This drug has been shown to be active in a variety of cancers, including breast cancer, prostate cancer, and lung cancer. Acolbifene binds to the estrogen receptor and prevents the activation of transcription factors necessary for gene expression. It also inhibits angiogenesis and inflammation by binding to enzymes involved in these processes. Acolbifene is used as treatment for autoimmune diseases such as rheumatoid arthritis. The drug has potent antagonistic activity against endogenous estrogens in a model system, but it is not active against other steroid hormones such as progesterone or testosterone.